Source Bioscience Share Discussion Threads

[bigman] 03/11/2015 07:35

I added to my holding last week and pleased to do so. Profitable cash generative businesses in this sector are as rare as hens teeth.

[buywell3] 19/10/2015 00:56

The BOD selling may well relate to the recent award of more share options several weeks back

The latest acquisition should add to revenue this year , so a profit of 3.5M looks on

A P/E of 20 then would not seem too demanding

[modform] 15/10/2015 11:59

If someone sells 2m shares at 17p, there's a keep buyer in the background. I would have thought such a large sell in the company of this szie would have driven the price down quite a bit.

[bartdude] 15/10/2015 09:11

DIRECTOR DEALINGS: SOURCE BIOSCIENCE CHAIRMAN SELLS 2 MILLION SHARES

[ 14 Oct 2015 10:12 ]
LONDON (Alliance News) - Source BioScience PLC on Wednesday said Chairman Laurence Turnbull sold 2 million shares at a price of 17 pence per share on Monday.

The deal was worth GBP340,000 gross.

Following this transaction, Turnbull has an interest in 2.8 million shares representing approximately 0.79% of the issued share capital.
???

???

[soupdragon55] 15/10/2015 08:17

Ah the classic "every sell is a buy" post.Nice to see you have a new handle buywell, why did you stop being no. 2?

[peterz] 14/10/2015 15:42

Director sells....wonderful!

[peterz] 11/10/2015 10:29

I have no problem with that.

[soupdragon55] 10/10/2015 09:04

Looks like the 6 months is up already.

[buywell3] 09/10/2015 23:25

9th Oct 5.75M shares traded at 17p so perhaps an RNS next week

Next Market Update should make interesting reading

I see there are now 21 agents selling Source BioScience Group Clones/Re-agents/Serology products etc

This is up from 18 agents some 6 months back so the 'Life Sciences' Division should start to show some benefit

[wilkie_hk] 17/9/2015 09:04

Buywell, I would also like to add my thanks for all the research that you have undertaken and shared with us on this message board. I can understand that by posting/presenting here it has assisted you to clarify your thoughts on the company in respect of the direction they are taking and their prospects. Your latter posts indicate that you are more confident than ever that the company has a well worked out strategy for growth into the future and that it will deliver, with the right people on board for this journey. I assume that, to an extent, you feel that there is now not the same need to spend the hours researching this company as, finally, the course is set. I certainly hope this is the case and if your share price projections come to fruition and we are at 25p in 15-18 months time, then I will be delighted with that.

[diamond1] 14/9/2015 08:52

Buywell,

I thought you knew. I've been a holder since Medical Solutions days.

[bigalan3] 13/9/2015 17:50

Buywell. Thank you for all your posts.

[peterz] 12/9/2015 09:11

Buywell enjoy the break. And thank you.

[buywell2] 12/9/2015 07:24

I am sure there are now a number of companies that are looking at what SBS is doing and achieving.

Thus far they have proved very adept at finding both value and good fits with the strategic acquisitions the BOD has made.

Institutional buying has proved that the market also likes what they see.

It would appear that SBS buys companies that it does business with or services in some way. This is clever because they know the ins and outs re orders/services made or supplied V the health of those other companies and thus their prospects.

Gradually SBS are broadening their client base both by cross selling to clients of the companies they acquire but are also beginning to enter other business areas or industries.

The range and depth of the abilities/skills of their staff , equipment, products and services that SBS have at their command continues to grow, take Select Pharma and Vindon Healthcare for example.

This makes a re-rating of the company based upon the changes that are taking place in the next few months look a virtual certainty.

I think 2016 will be a very good year ... and expect another acquisition that will take us to yet another level.

My call is 20p by this xmas

My call is 25p next year

I am now taking a break from posting for 6 months

dyor

[modform] 11/9/2015 19:06

ABC is my largest holding and have held it for a long time, so in a few years time SBS may become my largest, it reminds me of AMS which I have a small holding

[buywell2] 11/9/2015 15:59

Hello Diamond1 are you a SBS holder now ?

Shares Mags read some advfn BB's methinks





buywell3
29 Jul'15 - 08:23 - 3127 of 3213 0 0

A few thoughts

Source Bioscience had a presence in Biocity prior to this latest acquisition

From the Source Bioscience March 2015 results : 'Operational highlights

• Overnight Service™ for DNA sequencing launched from new laboratories in Los Angeles, BioCity Scotland and Tramore, Ireland


Presumably SBS had its eye on Select Pharma very soon after moving into Biocity if not before.

The acquisition of Vindon Healthcare was questioned by many.

Many investors sold up as they did not see the sense in acquiring a business that manufactured cold storage rooms.

Vindon was located in Rochdale, a new SBS production facility involving Inverclyde products has now been recently located nearby in the same Kingsway business park which allows for future product expansion



The latest Select Pharma acquisition also requires cold storage provision , not surprisingly one would imagine that Vindon units(now SBS owned) will be used in the future and most likely Select Pharma were already leasing some.


It does not take much out of the box thinking to expect SBS to replicate this model in the USA in a year or two.

The integration and replication of Select Pharma services at existing Source Bioscience USA facilities will surely come at some point soon, which will then enable greater market penetration particularly within the states concerned and the neighbouring states.

SBS has now made many acquisitions, this will be the sixth

Vindon was acquired by obtaining institutional cash at 9.5p , which was circa 23% discount on the circa 12.5p share price that SBS was trading at the time.

Select Pharma , which is a private unlisted company , has been acquired using institutional cash at raised at a share price of 14p which was the share price at the time of the announcement


Why is this ?


Private investors have all but sold out now

Over 90% of shares rested in the hands of existing institutional investors and SBS management BEFORE this acquisition

After the acquisition this figure will rise to over 95%

In short , there are hardly any shares left for PI's to trade.


The next acquisition which I expect will come within 18 months to two years , will be similar to this one with just one difference

I expect the cash raised next time will be at a premium to the SP


why ?


SBS turnover and profits for this year are already in the bag as there will be a whole years trading of Vindon products included PLUS there will be some numbers to add from Select Pharma , I now expect over £31.5m turnover ( just over a 20% 2014 rise )and this time over £3m profit, I don't expect too much in the way of charges/costs for the Select Pharma acquisition.

Also has anyone noticed that the number of distributors selling SBS Life Sciences products and services has increased to 18 from a recent 13 some 6 months ago ?

So a 2014 disappointing flat Life Sciences number should start heading north once more, plus Atlanta and the USA should start contributing.

2016 turnover and profits look set rise as there will be a whole year of Select Pharma turnover and profits to be added together with increased cross selling opportunities gained by SBS access to Select Pharma clients and vice versa


plus

there are no shares left so any new institution wanting a meaningful stake will have to pay for it.

SBS management, though I give them a hard time of it sometimes, are proving to be able to deliver the goods.

Their acquisition choices are coming good, have been bought at decent prices , the way that they are gelling together and each new one is helping the rest shows the plan is working.

Controlled growth by acquisition is the name of the game

SBS Market Cap is now over £50m , this might attract some new Institutions that have minimum market cap limits set for investment purposes.

Within 4 years I expect to see Turnover of £50m which will help to do the same

In short , SBS is starting to look like it might be another ABC


dyor

[diamond1] 11/9/2015 11:47

Share magazine says:

Momentum is building at this lab-service provider, which supports the pharmaceuticals industry and is a less risky play on drug development. The acquisition of of Select Pharma could lead to earnings upgrades.

It also gets a mention in today's Moneyweek.

[buywell3] 11/9/2015 07:04

I am not convinced that dirty instruments in this day and age pose a threat with the equipment and methods in place that exist to sterilize them.

However the creation of Alzheimers in a previously healthy person by means of dangerous ''acquired protein/s'' from a number of different sources such as injection of growth hormone, blood transfusions and donor organs is a BIG NEW development.

One which may well have implications in other diseases also.

Assays which can detect such damaging proteins look set to benefit greatly should the data in the above link gain credibility.

Such assays would I think fall into the Immunoassay category,
''An immunoassay is a biochemical test that measures the presence or concentration of a macromolecule in a solution through the use of an antibody or immunoglobulin. The macromolecule detected by the immunoassay is often referred to as an "analyte" and is in many cases a protein.''






From the Gaurdian link:
''Doctors examined the brains of eight CJD patients who had received pituitary growth hormone, given predominantly to children with stunted growth until it was stopped in 1985. Six of the brains had an unusual build-up of protein called amyloid beta, which has long been linked to Alzheimer’s disease. ''

Even with such a small sample , 6 out of 8 = 75%

Even 1 out of 8 would have been alarming , so I am convinced John Collinge is on to something that others will try to keep quiet for various reasons.

The ramifications are enormous.

''A 2012 article in the journal Methods of Molecular Biology noted the therapeutic protein products sector grossed US sales of $108 billion ''

Worth a read

FDA Draft Guidance Outlines Risk-Based Approach to Assessing Therapeutic Proteins

[peterz] 10/9/2015 22:07

Now the directors have cashed in perhaps we will get a few quid with the continued share price rerate?.

[buywell2] 09/9/2015 07:06

Interesting RNS today

Perhaps the monies will be used to buy into the next acquisition issue in 2016

[buywell2] 08/9/2015 10:09

I think you are correct

My guess is that Richard Griffiths is selling and probably Oryx International are adding.

The recent acquisition of Select Pharma is a VERY good one

The company is currently advertising for at least 6 positions , 2 quality control , several chemists and one technician TO MEET INCREASED WORKLOAD.

Select Pharma is a small company , this sudden increase in staff numbers must mean that the already ramping up of orders and turnover towards £2m that was taking place PRIOR to SBS buying them must now be gaining momentum due to additional orders from Source BioScience Group clients.

We still had 4 months of 2015 for Select Pharma to add to anticipated turnover

A profit of over £3.5M looks assured

The Source BioScience Group has gained .... Mastery of Acquisition Growth Strategy.

Another one please in 2016